BPC-157 · research summary

BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.

Pharmaceuticals (Basel, Switzerland) · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Review article defending the safety and efficacy of BPC 157 against previous critical reviews
“Thereby, we defend stable gastric pentadecapeptide BPC 157 therapy, efficacy, pleiotropic beneficial effects along with high safety (LD1 not achieved) against Józwiak and collaborators’ review speculating its negative impact, speculation of angiogenesis toward tumorogenesis, increased NO and eNOS, toward damaging free radicals formation, and neurodegenerative diseases (Parkinson’s disease and Alzheimer’s disease).”

Reported findings

BPC 157 opposes corneal neovascularization and exhibits anti-tumor potential in vivo and in vitro
“BPC 157 resolved cornea transparency maintenance, cornea healing “angiogenic privilege” (vs. angiogenesis/neovascularization/tumorogenesis), does not produce corneal neovascularization, but rather opposes it, and per Folkman’s concept, it demonstrates anti-tumor effect in vivo and in vitro.”
BPC 157 counteracts pathological presentations of neurodegenerative diseases in animal models
“Contrarily, in wound healing and general healing capabilities as reviewed, as a cytoprotective agent, and native cytoprotection mediator, BPC 157 controls angiogenesis and the NO-system healing functions, and counteracts the pathological presentation of neurodegenerative diseases in acknowledged animal models (i.e., Parkinson’s disease and Alzheimer’s disease), and presents prominent anti-tumor potential, in vivo and in vitro.”

Limitations stated by the authors

Human data are scarce and some studies lacked large sample sizes, ethnic variation, and sham control groups
“Furthermore, the scarce human studies so far done, regardless of all of the limitations in some of them (i.e., lacked a large sample size, ethnic variation, and sham control group) without adverse effects [34,35,36,37,38], encompassed a wide range of investigations (i.e., ulcerative colitis (double-blind phase II study) [34,35], knee pain [36], interstitial cystitis [37]).”

Source: PubMed 41155565 · DOI 10.3390/ph18101450 · all study summaries

Study type

Review article defending the safety and efficacy of BPC 157 against previous critical reviews

“Thereby, we defend stable gastric pentadecapeptide BPC 157 therapy, efficacy, pleiotropic beneficial effects along with high safety (LD1 not achieved) against Józwiak and collaborators’ review speculating its negative impact, speculation of angiogenesis toward tumorogenesis, increased NO and eNOS, toward damaging free radicals formation, and neurodegenerative diseases (Parkinson’s disease and Alzheimer’s disease).”

Reported findings

BPC 157 opposes corneal neovascularization and exhibits anti-tumor potential in vivo and in vitro

“BPC 157 resolved cornea transparency maintenance, cornea healing “angiogenic privilege” (vs. angiogenesis/neovascularization/tumorogenesis), does not produce corneal neovascularization, but rather opposes it, and per Folkman’s concept, it demonstrates anti-tumor effect in vivo and in vitro.”

BPC 157 counteracts pathological presentations of neurodegenerative diseases in animal models

“Contrarily, in wound healing and general healing capabilities as reviewed, as a cytoprotective agent, and native cytoprotection mediator, BPC 157 controls angiogenesis and the NO-system healing functions, and counteracts the pathological presentation of neurodegenerative diseases in acknowledged animal models (i.e., Parkinson’s disease and Alzheimer’s disease), and presents prominent anti-tumor potential, in vivo and in vitro.”

Limitations stated by the authors

Human data are scarce and some studies lacked large sample sizes, ethnic variation, and sham control groups

“Furthermore, the scarce human studies so far done, regardless of all of the limitations in some of them (i.e., lacked a large sample size, ethnic variation, and sham control group) without adverse effects [34,35,36,37,38], encompassed a wide range of investigations (i.e., ulcerative colitis (double-blind phase II study) [34,35], knee pain [36], interstitial cystitis [37]).”